Overview

We are dedicated to the formulation and development of novel liquid medications with child-friendly flavors for orphan diseases that will improve the quality of lives in pediatric patients. NuCelecoxib™ our most advanced candidate is a child appropriate liquid formulation of celecoxib that will replace current capsule dosing of celebrex® in children. NuCelecoxib™ is granted Orphan-Drug designation by the FDA for the treatment of Juvenile Idiopathic Arthritis. NuBioPharma is actively seeking a developmental partner or a full licensee for Nu-Celecoxib™ Oral Liquid Suspension of celecoxib for Juvenile Idiopathic Arthritis. www.nubiopharma.com